Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Österreich)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,761 GBX | -0.63% |
|
-5.78% | -7.92% |
| Feb. 09 | ASTRAZENECA : Deutsche Bank downgrades to 'sell | CF |
| Feb. 09 | This time it's for real |  |
Financials (USD)
| Sales 2023 | 45.81B | Sales 2024 * | 50.81B | Capitalization | 191B |
|---|---|---|---|---|---|
| Net income 2023 | 5.96B | Net income 2024 * | 9.14B | EV / Sales 2023 | 4.57 x |
| Net Debt 2023 * | 21.64B | Net Debt 2024 * | 17.57B | EV / Sales 2024 * | 4.11 x |
| P/E ratio 2023 |
35.4
x | P/E ratio 2024 * |
21
x | Employees | 83,500 |
| Yield 2023 * |
2.43% | Yield 2024 * |
2.52% | Free-Float | 96.46% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | -0.63% | ||
| 1 week | -5.78% | ||
| Current month | -7.04% | ||
| 1 month | -10.47% | ||
| 3 months | -6.47% | ||
| 6 months | -12.71% | ||
| Current year | -7.92% |
1 week
9 700.00
10 652.00
1 month
9 700.0011 022.00
Current year
9 700.0011 022.00
1 year
9 700.0012 392.00
3 years
6 736.0012 392.00
5 years
5 626.0012 392.00
10 years
3 680.0012 392.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 63 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 190 M€ | +3.64% | ||
| 5.17% | 19 M€ | +2.97% | - | |
| 4.89% | 725 M€ | -2.15% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-02-09 | 9,761 | -0.63% | 5,562,494 |
| 24-02-08 | 9,823 | -6.36% | 6,500,973 |
| 24-02-07 | 10,490 | -0.42% | 2,075,810 |
| 24-02-06 | 10,534 | +1.68% | 1,552,211 |
| 24-02-05 | 10,360 | 0.00% | 1,682,817 |
Delayed Quote London S.E., February 09, 2024 at 11:35 am EST
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (96.9%). Net sales break down by treatment area between oncology (34%), cardiovascular, renal and metabolic diseases (21.4%), respiratory and autoimmune diseases (13.4%), and other (31.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (3.1%).
Net sales are distributed geographically as follows: the United Kingdom (7%), Europe (20.1%), Americas (44.2%) and Africa/Asia/Australia (28.7%).
Sector
Pharmaceuticals
Calendar
2024-02-11
- Roadshow - Day 1
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
123.3
USD
Average target price
162.9
USD
Spread / Average Target
+32.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.92% | 191 B $ | |
| +26.97% | 666 B $ | |
| +19.17% | 536 B $ | |
| +0.01% | 377 B $ | |
| +15.07% | 318 B $ | |
| +12.33% | 307 B $ | |
| -8.02% | 207 B $ | |
| +4.05% | 206 B $ | |
| -4.27% | 156 B $ | |
| -3.63% | 117 B $ |
